Evidence map›Paper›PMID 26906030›Full record

Trial reportWorld journal of urology2016

Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study.

Michael D Bell, Faysal A Yafi, Fadi Brimo, Jordan Steinberg, Armen G Aprikian, Simon Tanguay, Wassim Kassouf

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in World journal of urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Urinary hyaluronic acid: a versatile marker of bladder cancer.International urology and nephrology · 2020
    Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Active surveillance for nonmuscle invasive bladder cancer.Investigative and clinical urology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michael D BellDepartment of Surgery (Urology), McGill University, Montreal, QC, Canada.
Faysal A YafiDepartment of Surgery (Urology), McGill University, Montreal, QC, Canada.
Fadi BrimoDepartment of Surgery (Urology), McGill University, Montreal, QC, Canada.
Jordan SteinbergDepartment of Surgery (Urology), McGill University, Montreal, QC, Canada.
Armen G AprikianDepartment of Surgery (Urology), McGill University, Montreal, QC, Canada.
Simon TanguayDepartment of Surgery (Urology), McGill University, Montreal, QC, Canada.
Wassim KassoufDepartment of Surgery (Urology), McGill University, Montreal, QC, Canada. wassim.kassouf@muhc.mcgill.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeUrinary cytology (C) and cystoscopy remain the gold standard for the detection and screening of bladder cancer (BC). In this prospective study, we analyzed whether baseline C, ImmunoCyt (I), BTA Stat (B), hemoglobin dipstick (H), and NMP22 BladderChek (N) can predict recurrence and progression.

methodsUrinary samples from 91 patients with BC were prospectively collected over an 18-month period. Baseline characteristics of the population included patient demographics, various clinicopathological variables and use of intravesical therapy. Progression and recurrence were then assessed after a median follow-up of 48 months (IQR 23.7-59.5). Univariate and multivariate analyses were performed using COX proportional hazards models.

resultsOn univariate analysis, C (HR 1.36; p = 0.26), I (HR 0.89; p = 0.66), B (HR 0.80; p = 0.42), H (HR 0.75; p = 0.30), and N (HR 0.82; p = 0.48) were not associated with recurrence-free survival (RFS). With regard to progression-free survival (PFS), C was significantly prognostic (HR 2.67; p = 0.017), whereas I, B, H, and N were not. On multivariable analysis, NMP22 was the only marker to be independently associated with RFS (HR 0.41, p < 0.01) and PFS (HR 0.32, p = 0.02).

conclusionBased on the results of this study, baseline C, B, I, and H were not independently prognostic. Prognostic impact of NMP22 requires further validation in a multicenter larger study.

Indexed as

AgedAged, 80 and overBiomarkers, TumorCanadaCystoscopyDisease-Free SurvivalDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisProportional Hazards ModelsProspective StudiesBiomarkers, TumorBladder cancerProgressionRecurrenceUrinary biomarkersUrinary cytology

Identifiers

PMID26906030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.